Lipfendra, the first once-daily oral PCSK9 inhibitor, was shown to reduce LDL cholesterol by roughly 56% to 60% when combined with statins.
Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor.
Merck, the New Jersey-based manufacturer of Lipfendra … [+2928 chars]
Merck, the New Jersey-based manufacturer of Lipfendra … [+2928 chars]